Exacerbation of cerebrospinal fluid (CSF)
inflammation in response to bacteriolysis by
beta-lactam antibiotics contributes to brain damage and neurological sequelae in
bacterial meningitis.
Daptomycin, a nonlytic
antibiotic acting on Gram-positive bacteria, lessens
inflammation and
brain injury compared to
ceftriaxone. With a view to a clinical application for pediatric
bacterial meningitis, we investigated the effect of combining
daptomycin or
rifampin with
ceftriaxone in an infant rat
pneumococcal meningitis model. Eleven-day-old Wistar rats with
pneumococcal meningitis were randomized to treatment starting at 18 h after
infection with (i)
ceftriaxone (100 mg/kg of
body weight, subcutaneously [s.c.], twice a day [b.i.d.]), (ii)
daptomycin (10 mg/kg, s.c., daily) followed 15 min later by
ceftriaxone, or (iii)
rifampin (20 mg/kg, intraperitoneally [i.p.], b.i.d.) followed 15 min later by
ceftriaxone. CSF was sampled at 6 and 22 h after the initiation of
therapy and was assessed for concentrations of defined
chemokines and
cytokines. Brain damage was quantified by histomorphometry at 40 h after
infection and
hearing loss was assessed at 3 weeks after
infection.
Daptomycin plus
ceftriaxone versus
ceftriaxone significantly (P < 0.04) lowered CSF concentrations of
monocyte chemoattractant protein 1 (MCP-1), MIP-1α, and
interleukin 6 (IL-6) at 6 h and MIP-1α,
IL-6, and
IL-10 at 22 h after initiation of
therapy, led to significantly (P < 0.01) less apoptosis, and significantly (P < 0.01) improved hearing capacity. While
rifampin plus
ceftriaxone versus
ceftriaxone also led to lower CSF
inflammation (P < 0.02 for IL-6 at 6 h), it had no significant effect on apoptosis and hearing capacity. Adjuvant
daptomycin could therefore offer added benefits for the treatment of pediatric
pneumococcal meningitis.